Since the introduction of the first monoclonal antibody, biopharmaceuticals and biotherapeutic products manufactured in cellular factories are on the rise in modern medicine and therapeutics. Dynamic and real-time innovation strategies for operational implementation of biotherapeutic production are rapidly emerging. The advances in related fields such as genome editing technology, systems biology, and machine learning/artificial intelligence are expected to introduce innovative solutions in every aspect of the mammalian cell culture-based biotherapeutic production. This conceptual review offers a synthesis of the prospects and challenges of integration of multiomics technologies, and an integrative biology vision to cellular factories and biotherapeutic innovation.
Get full access to this article
View all access options for this article.
References
1.
AhnWS, and AntoniewiczMR. (2011). Metabolic flux analysis of CHO cells at growth and non-growth phases using isotopic tracers and mass spectrometry. Metab Eng, 13, 598–609.
2.
AldenN, KrishnanS, PorokhinV, et al. (2017). Biologically consistent annotation of metabolomics data. Anal Chem, 89, 13097–13104.
3.
AliA, AbouleilaY, ShimizuY, et al. (2019a). Single-cell metabolomics by mass spectrometry: Advances, challenges, and future applications. Trends in Analytical Chemistry, 120, 115436.
4.
AliAS, RajuR, KshirsagarR, et al. (2019b). Multi-Omics Study on the Impact of Cysteine Feed Level on Cell Viability and mAb Production in a CHO Bioprocess. Biotechnol J, 14, 1800352.
5.
BakerM. (2011). Metabolomics: From small molecules to big ideas. Nat Methods, 8, 117.
6.
BarupalDK, FanS, and FiehnO. (2018). Integrating bioinformatics approaches for a comprehensive interpretation of metabolomics datasets. Curr Opin Biotechnol, 54, 1–9.
7.
BeckA, GoetschL, DumontetC, and CorvaïaN. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov, 16, 315.
8.
BeckA, Wagner-RoussetE, AyoubD, Van DorsselaerA, and Sanglier-CianféraniS. (2013). Characterization of therapeutic antibodies and related products. Analyt Chem, 85, 715–736.
9.
Ben YahiaB, GourevitchB, MalphettesL, and HeinzleE. (2017). Segmented linear modeling of CHO fed-batch culture and its application to large scale production. Biotechnol Bioeng, 114, 785–797.
10.
BroadhurstD, GoodacreR, ReinkeSN, et al. (2018). Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics, 14, 72.
11.
BuchsteinerM, QuekL-E, GrayP, and NielsenLK. (2018). Improving culture performance and antibody production in CHO cell culture processes by reducing the Warburg effect. Biotechnol Bioeng, 115, 2315–2327.
12.
CabatonNJ, PoupinN, CanletC, et al. (2018). An untargeted metabolomics approach to investigate the metabolic modulations of HepG2 cells exposed to low doses of bisphenol A and 17β-estradiol. Front Endocrinol, 9, 571.
13.
ChappellL, RussellAJC, and VoetT. (2018). Single-cell (multi)omics technologies. Annu Rev Genomics Human Genet, 19, 15–41.
14.
DahodwalaH, and LeeKH. (2019). The fickle CHO: A review of the causes, implications, and potential alleviation of the CHO cell line instability problem. Curr Opin Biotechnol, 60, 128–137.
15.
DeanJ, and ReddyP. (2013). Metabolic analysis of antibody producing CHO cells in fed-batch production. Biotechnol Bioeng, 110, 1735–1747.
16.
Dick JrLW, QiuD, MahonD, AdamoM, and ChengK-C. (2008). C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes. Biotechnol Bioeng, 100, 1132–1143.
17.
DicksonAJ. (2014). Enhancement of production of protein biopharmaceuticals by mammalian cell cultures: The metabolomics perspective. Curr Opin Biotechnol, 30, 73–79.
18.
EisenreichW, RudelT, HeesemannJ, and GoebelW. (2019). How viral and intracellular bacterial pathogens reprogram the metabolism of host cells to allow their intracellular replication. Front Cell Infect Microbiol, 9, 42.
19.
EvieIM, DicksonAJ, and ElvinM. (2017). Metabolite profiling of mammalian cell culture processes to evaluate cellular viability. In: Cell Viability Assays: Methods and Protocols. Gilbert DF, Friedrich O, eds. New York, NY: Springer New, York, 137–152.
20.
FarrellA, McLoughlinN, MilneJJ, MarisonIW, and BonesJ. (2014). Application of multi-omics techniques for bioprocess design and optimization in Chinese Hamster Ovary Cells. J Proteome Res, 13, 3144–3159.
21.
FeketeS, GuillarmeD, SandraP, and SandraK. (2016). Chromatographic, Electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals. Anal Chem, 88, 480–507.
22.
FischerS, HandrickR, and OtteK. (2015). The art of CHO cell engineering: A comprehensive retrospect and future perspectives. Biotechnol Adv, 33, 1878–1896.
23.
FrançoisY-N, BiacchiM, SaidN, et al. (2016). Characterization of cetuximab Fc/2 dimers by off-line CZE-MS. Anal Chim Acta, 908, 168–176.
24.
GahoualR, BeckA, Leize-WagnerE, and FrançoisY-N. (2016). Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products. J Chromatogr B, 1032, 61–78.
25.
GahoualR, Leize-WagnerE, HouzéP, and FrançoisY-N. (2019). Revealing the potential of capillary electrophoresis/mass spectrometry: The tipping point. Rapid Commun Mass Spectr, 33, 11–19.
26.
GalbraithSC, BhatiaH, LiuH, and YoonS. (2018). Media formulation optimization: Current and future opportunities. Curr Opin Chem Eng, 22, 42–47.
27.
GalleguillosSN, RuckerbauerD, GerstlMP, BorthN, HanschoM, and ZanghelliniJ. (2017). What can mathematical modelling say about CHO metabolism and protein glycosylation?. Comput Struct Biotechnol J, 15, 212–221.
28.
GolabgirA, GutierrezJM, HefziH, et al. (2016). Quantitative feature extraction from the Chinese hamster ovary bioprocess bibliome using a novel meta-analysis workflow. Biotechnol Adv, 34, 621–633.
29.
HanM, RockBM, PearsonJT, and RockDA. (2016). Intact mass analysis of monoclonal antibodies by capillary electrophoresis—Mass spectrometry. J Chromatogr B, 1011, 24–32.
30.
HaradaS, HirayamaA, ChanQ, et al. (2018). Reliability of plasma polar metabolite concentrations in a large-scale cohort study using capillary electrophoresis-mass spectrometry. PLoS One, 13, e0191230.
31.
HaselbergR, de JongGJ, and SomsenGW. (2013). Low-flow sheathless capillary electrophoresis–mass spectrometry for sensitive glycoform profiling of intact pharmaceutical proteins. Anal Chem, 85, 2289–2296.
32.
HaselbergR, De VijlderT, HeukersR, et al. (2018). Heterogeneity assessment of antibody-derived therapeutics at the intact and middle-up level by low-flow sheathless capillary electrophoresis-mass spectrometry. Anal Chim Acta, 1044, 181–190.
33.
HefziH, AngKS, HanschoM, et al. (2016). A consensus genome-scale reconstruction of Chinese Hamster ovary cell metabolism. Cell Syst, 3, 434–443.e438.
34.
HsuH-H, ArakiM, MochizukiM, et al. (2017). A systematic approach to time-series metabolite profiling and RNA-seq analysis of Chinese hamster ovary cell culture. Sci Rep, 7, 43518.
35.
HuangZ, LeeD-Y, and YoonS. (2017). Quantitative intracellular flux modeling and applications in biotherapeutic development and production using CHO cell cultures. Biotechnol Bioeng, 114, 2717–2728.
36.
JiangM, SeversonKA, LoveJC, et al. (2017). Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing. Biotechnol Bioeng, 114, 2445–2456.
37.
JusticeC, BrixA, FreimarkD, et al. (2011). Process control in cell culture technology using dielectric spectroscopy. Biotechnol Adv, 29, 391–401.
38.
KaasCS, KristensenC, BetenbaughMJ, and AndersenMR. (2015). Sequencing the CHO DXB11 genome reveals regional variations in genomic stability and haploidy. BMC Genomics, 16, 160.
39.
KammeijerGSM, JansenBC, KohlerI, et al. (2017). Sialic acid linkage differentiation of glycopeptides using capillary electrophoresis – electrospray ionization – mass spectrometry. Sci Rep, 7, 3733.
40.
KastelicM, KopačD, NovakU, and LikozarB. (2019). Dynamic metabolic network modeling of mammalian Chinese hamster ovary (CHO) cell cultures with continuous phase kinetics transitions. Biochem Eng J, 142, 124–134.
41.
KelleyB, KissR, and LairdM. (2018). a different perspective: How much innovation is really needed for monoclonal antibody production using mammalian cell technology? In: New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins. Kiss B, Gottschalk U, and Pohlscheidt M, eds. Cham: Springer International, Publishing, 443–462.
42.
KilkK. (2019). Metabolomics horizon scanning for 2020: Three actionable challenges. OMICS, 24, 51–52.
43.
KimJ, ChoiK, and ChungDS. (2019). Synergistic coupling of in-line single-drop microextraction and on-line large-volume sample stacking for capillary electrophoresis/mass spectrometry. Anal Bioanal Chem, 411, 1067–1073.
44.
KimJY, KimY-G, and LeeGM. (2012). CHO cells in biotechnology for production of recombinant proteins: Current state and further potential. Appl Microbiol Biotechnol, 93, 917–930.
45.
KimuraS, and OmasaT. (2018). Genome sequence comparison between Chinese hamster ovary (CHO) DG44 cells and mouse using end sequences of CHO BAC clones based on BAC-FISH results. Cytotechnology, 70, 1399–1407.
46.
KnezevicI, and GriffithsE. (2017). WHO standards for biotherapeutics, including biosimilars: An example of the evaluation of complex biological products. Ann N Y Acad Sci, 1407, 5–16.
47.
KokMGM, SomsenGW, and de JongGJ. (2014). The role of capillary electrophoresis in metabolic profiling studies employing multiple analytical techniques. Trends Anal Chem, 61, 223–235.
48.
KrollP, HoferA, UlonskaS, KagerJ, and HerwigC. (2017). Model-based methods in the biopharmaceutical process lifecycle. Pharm Res, 34, 2596–2613.
49.
KumarN, GammellP, and ClynesM. (2007). Proliferation control strategies to improve productivity and survival during CHO based production culture: A summary of recent methods employed and the effects of proliferation control in product secreting CHO cell lines. Cytotechnology, 53, 33–46.
50.
KuoC-C, ChiangAWT, ShamieI, SamoudiM, GutierrezJM, and LewisNE. (2018). The emerging role of systems biology for engineering protein production in CHO cells. Curr Opin Biotechnol, 51, 64–69.
51.
LalondeM-E, and DurocherY. (2017). Therapeutic glycoprotein production in mammalian cells. J Biotechnol, 251, 128–140.
52.
LechnerA, GiorgettiJ, GahoualR, BeckA, Leize-WagnerE, and FrançoisY-N. (2019). Insights from capillary electrophoresis approaches for characterization of monoclonal antibodies and antibody drug conjugates in the period 2016–2018. J Chromatogr B, 1122–1123, 1–17.
53.
LeeJW. (2013). ADME of monoclonal antibody biotherapeutics: Knowledge gaps and emerging tools. Bioanalysis, 5, 2003–2014.
54.
Le-MinhV, TranNT, MakkyA, RosilioV, TavernaM, and SmadjaC. (2019). Capillary zone electrophoresis-native mass spectrometry for the quality control of intact therapeutic monoclonal antibodies. J Chromatogr A, 1601, 375–384.
55.
LewC, Gallegos-PerezJ-L, FonslowB, LiesM, and GuttmanA. (2015). Rapid level-3 characterization of therapeutic antibodies by capillary electrophoresis electrospray ionization mass spectrometry. J Chromatogr Sci, 53, 443–449.
56.
LewisAM, Abu-AbsiNR, BorysMC, and LiZJ. (2016). The use of ‘Omics technology to rationally improve industrial mammalian cell line performance. Biotechnol Bioeng, 113, 26–38.
57.
LeyD, SereshtAK, EngmarkM, et al. (2015). Multi-omic profiling of EPO-producing Chinese hamster ovary cell panel reveals metabolic adaptation to heterologous protein production. Biotechnol Bioeng, 112, 2373–2387.
58.
LiF, VijayasankaranN, ShenA, KissR, and AmanullahA. (2010). Cell culture processes for monoclonal antibody production. mAbs, 2, 466–479.
59.
LillJR. (2017). Introduction to biotherapeutics. Eds: Lill JR and Sandoval W: Analytical Characterization of Biotherapeutics, John Wiley and Sons, United States. pp. 1–14.
60.
LimY, WongNSC, LeeYY, KuSCY, WongDCF, and YapMGS. (2010). Engineering mammalian cells in bioprocessing—Current achievements and future perspectives. Biotechnol Appl Biochem, 55, 175–189.
61.
LiuJ-X, AertsJT, RubakhinSS, ZhangX-X, and SweedlerJV. (2014). Analysis of endogenous nucleotides by single cell capillary electrophoresis-mass spectrometry. Analyst, 139, 5835–5842.
62.
LiuYD, GoetzeAM, BassRB, and FlynnGC. (2011). N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. J Biol Chem, 286, 11211–11217.
63.
LiuZ, PorteroEP, JianY, et al. (2019). Trace, machine learning of signal images for trace-sensitive mass spectrometry: A case study from single-cell metabolomics. Anal Chem, 91, 5768–5776.
64.
LongNP, ParkS, AnhNH, et al. (2020). Advances in liquid chromatography–mass spectrometry-based lipidomics: A look ahead. J Anal Test, 4, 183–197.
65.
MariñoK, BonesJ, KattlaJJ, and RuddPM. (2010). A systematic approach to protein glycosylation analysis: A path through the maze. Nat Chem Biol, 6, 713–723.
66.
MiggielsP, WoutersB, van WestenGJP, DubbelmanA-C, and HankemeierT. (2018). Novel technologies for metabolomics: More for less. Trends Analyt Chem, 120, 115323.
67.
Mohmad-SaberiSE, HashimYZH-Y, MelM, et al. (2013). Metabolomics profiling of extracellular metabolites in CHO-K1 cells cultured in different types of growth media. Cytotechnology, 65, 577–586.
68.
MongeME, DoddsJN, BakerES, EdisonAS, and FernándezFM. (2019). Challenges in identifying the dark molecules of life. Annu Rev Analyt Chem, 12, 177–199.
69.
NaikHM, MajewskaNI, and BetenbaughMJ. (2018). Impact of nucleotide sugar metabolism on protein N-glycosylation in Chinese Hamster Ovary (CHO) cell culture. Curr Opin Chem Eng, 22, 167–176.
70.
NazS, Moreira dos SantosDC, GarcíaA, and BarbasC. (2014). Analytical protocols based on LC–MS, GC–MS and CE–MS for nontargeted metabolomics of biological tissues. Bioanalysis, 6, 1657–1677.
71.
NelsonAL, DhimoleaE, and ReichertJM. (2010). Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov, 9, 767.
72.
NeumannEK, DoTD, ComiTJ, and SweedlerJV. (2019). Exploring the fundamental structures of life: Non-targeted, chemical analysis of single cells and subcellular structures. Angew Chem Int Ed, 58, 9348–9364.
73.
ObrezanovaO, ArnellA, de la CuestaRG, et al. (2015). Aggregation risk prediction for antibodies and its application to biotherapeutic development. mAbs, 7, 352–363.
74.
PaisDAM, CarrondoMJT, AlvesPM, and TeixeiraAP. (2014). Towards real-time monitoring of therapeutic protein quality in mammalian cell processes. Curr Opin Biotechnol, 30, 161–167.
75.
PereiraS, KildegaardHF, and AndersenMR. (2018). Impact of CHO metabolism on cell growth and protein production: An overview of toxic and inhibiting metabolites and nutrients. Biotechnol J, 13, 1700499.
76.
PoppO, MüllerD, DidzusK, et al. (2016). A hybrid approach identifies metabolic signatures of high-producers for chinese hamster ovary clone selection and process optimization. Biotechnol Bioeng, 113, 2005–2019.
77.
PrusinkiewiczMA, and MymrykJS. (2019). Metabolic reprogramming of the host cell by human adenovirus infection. Viruses, 11, 141.
78.
RamautarR, BergerR, van der GreefJ, and HankemeierT. (2013). Human metabolomics: Strategies to understand biology. Curr Opin Chem Biol, 17, 841–846.
79.
RamautarR, SomsenGW, and de JongGJ. (2009). CE-MS in metabolomics. Electrophoresis, 30, 276–291.
80.
RamautarR, SomsenGW, and de JongGJ. (2015). CE-MS for metabolomics: Developments and applications in the period 2012–2014. Electrophoresis, 36, 212–224.
81.
RamautarR, SomsenGW, and de JongGJ. (2017). CE–MS for metabolomics: Developments and applications in the period 2014–2016. Electrophoresis, 38, 190–202.
82.
RamautarR, SomsenGW, and de JongGJ. (2019). CE-MS for metabolomics: Developments and applications in the period 2016–2018. Electrophoresis, 40, 165–179.
83.
RedmanEA, MellorsJS, StarkeyJA, and RamseyJM. (2016). Characterization of intact antibody drug conjugate variants using microfluidic capillary electrophoresis–mass spectrometry. Anal Chem, 88, 2220–2226.
84.
RichelleA, and LewisNE. (2017). Improvements in protein production in mammalian cells from targeted metabolic engineering. Curr Opin Syst Biol, 6, 1–6.
85.
RitaccoFV, WuY, and KhetanA. (2018). Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies. Biotechnol Progr, 34, 1407–1426.
86.
RobaskyK, LewisNE, and ChurchGM. (2013). The role of replicates for error mitigation in next-generation sequencing. Nat Rev Genet, 15, 56.
87.
RogersRS, NightlingerNS, LivingstonB, CampbellP, BaileyR, and BallandA. (2015). Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. mAbs, 7, 881–890.
88.
SandraK, VandenheedeI, and SandraP. (2014). Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization. J Chromatogr A, 1335, 81–103.
89.
Schrimpe-RutledgeAC, CodreanuSG, SherrodSD, and McLeanJA. (2016). Untargeted metabolomics strategies—challenges and emerging directions. J Am Soc Mass Spectr, 27, 1897–1905.
90.
SertbasM, and UlgenKO. (2018). Unlocking human brain metabolism by genome-scale and multiomics metabolic models: Relevance for neurology research, health, and disease. OMICS, 22, 455–467.
91.
ShanmuganathanM, and Britz-McKibbinP. (2019). New advances in amino acid profiling in biological samples by capillary electrophoresis-mass spectrometry. In: Amino Acid Analysis: Methods and Protocols. Alterman MA, ed. New York, NY: Springer New, York, 327–350.
92.
ShuklaS, and GuptaV. (2020). Analytical challenges and advancements in bioanalysis of therapeutic proteins. Bioanalysis, 12, 207–209.
93.
SifniotisV, CruzE, ErogluB, and KayserV. (2019). Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation. Antibodies, 8, 36.
94.
SommereggerW, SissolakB, KandraK, von StoschM, MayerM, and StriednerG. (2017). Quality by control: Towards model predictive control of mammalian cell culture bioprocesses. Biotechnol J, 12, 1600546.
95.
SrivastavaA, KowalskiGM, CallahanDL, MeiklePJ, and CreekDJ. (2016). Strategies for extending metabolomics studies with stable isotope labelling and fluxomics. Metabolites, 6, 32.
96.
StolfaG, SmonskeyMT, BonifaceR, et al. (2018). CHO-omics review: The impact of current and emerging technologies on Chinese Hamster ovary based bioproduction. Biotechnol J, 13, 1700227.
97.
StoreyJD, and TibshiraniR. (2003). Statistical significance for genomewide studies. Proc Natl Acad Sci, 100, 9440.
98.
SzigetiM, ChapmanJ, BorzaB, and GuttmanA. (2018). Quantitative assessment of mAb Fc glycosylation of CQA importance by capillary electrophoresis. Electrophoresis, 39, 2340–2343.
99.
TempletonN, XuS, RoushDJ, and ChenH. (2017). 13C metabolic flux analysis identifies limitations to increasing specific productivity in fed-batch and perfusion. Metab Eng, 44, 126–133.
100.
TharmalingamT, WuC-H, CallahanS.T., and GoudarC. (2015). A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture. Biotechnol Bioeng, 112, 1146–1154.
101.
TibbittsJ, CanterD, GraffR, SmithA, and KhawliLA. (2016). Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. mAbs, 8, 229–245.
102.
TournayV, JacomyM, NeculaA, LeibingA, and BlasimmeA. (2019). A new web-based big data analytics for dynamic public opinion mapping in digital networks on contested biotechnology fields. OMICS, 24, 29–42.
103.
VinegoniC, DubachJM, ThurberGM, MillerMA, MazitschekR, and WeisslederR. (2015). Advances in measuring single-cell pharmacology in vivo. Drug Discov Today, 20, 1087–1092.
104.
VishwanathanN, LeH, LeT, and HuW-S. (2014). Advancing biopharmaceutical process science through transcriptome analysis. Curr Opin Biotechnol, 30, 113–119.
105.
VodopivecM, LahL, NaratM, and CurkT. (2019). Metabolomic profiling of CHO fed-batch growth phases at 10, 100, and 1,000 L. Biotechnol Bioeng, 116, 2720–2729.
106.
VoetenRLC, VentouriIK, HaselbergR, and SomsenGW. (2018). Capillary electrophoresis: Trends and recent advances. Anal Chem, 90, 1464–1481.
WangQ, BaoB, ChenY, and DaiN. (2013). Simultaneous determination of six flavonoids in rat plasma by high-performance capillary electrophoresis and its application to a pharmacokinetic study. J Food Drug Anal, 21, 369–375.
110.
WenzC, BarbasC, López-Gonzálvez Á, et al. (2015). Interlaboratory study to evaluate the robustness of capillary electrophoresis-mass spectrometry for peptide mapping. J Sep Sci, 38, 3262–3270.
111.
WHO. (2013). Guidelines on the Quality, Safety, and Efficacy of Biotherapeutic Protein Products Prepared by Recombinant DNA Technology. World Health Organization,Switzerland.
112.
WurmFM. (2013). CHO Quasispecies—Implications for manufacturing processes. Processes, 1, 296–311.
113.
XiaJQ. (2016). Separation and characterization of proteins and peptides in biological fluids using CE-MS. In: Capillary Electrophoresis-Mass Spectrometry: Therapeutic Protein Characterization. Xia JQ, Zhang L, eds. Cham: Springer International, Publishing, 35–38.
114.
XuX, NagarajanH, LewisNE, et al. (2011). The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol, 29, 735–741.
115.
YangK, and HanX. (2016). Lipidomics: Techniques, applications, and outcomes related to biomedical sciences. Trends Biochem Sci, 41, 954–969.
116.
Yaşar YildizS, NikerelE, and Toksoy ÖnerE. (2019). Genome-scale metabolic model of a microbial cell factory (Brevibacillus thermoruber 423) with multi-industry potentials for exopolysaccharide production. OMICS, 23, 237–246.
117.
YuanM, BreitkopfSB, YangX, and AsaraJM. (2012). A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc, 7, 872.
118.
YusufiFNK, LakshmananM, HoYS, et al. (2017). Mammalian systems biotechnology reveals global cellular adaptations in a recombinant CHO cell line. Cell Syst, 4, 530–542.e536.
119.
ZamboniN, SaghatelianA, and PattiGJ. (2015). Defining the metabolome: Size, flux, and regulation. Mol Cell, 58, 699–706.
ZhangR, WuH, HeM, ZhangW, and XuW. (2019a). Mobility capillary electrophoresis-restrained modeling method for protein structure analysis in mixtures. J Phys Chem B, 123, 2335–2341.
122.
ZhangW, HankemeierT, and RamautarR. (2017). Next-generation capillary electrophoresis–mass spectrometry approaches in metabolomics. Curr Opin Biotechnol, 43, 1–7.
123.
ZhangW, WuH, ZhangR, FangX, and XuW. (2019b). Structure and effective charge characterization of proteins by a mobility capillary electrophoresis based method. Chem Sci, 10, 7779–7787.
124.
ZhaoSS, ZhongX, TieC, and ChenDDY. (2012). Capillary electrophoresis-mass spectrometry for analysis of complex samples. Proteomics, 12, 2991–3012.
125.
ZhuG, SunL, Heidbrink-ThompsonJ, et al. (2016). Capillary zone electrophoresis tandem mass spectrometry detects low concentration host cell impurities in monoclonal antibodies. Electrophoresis, 37, 616–622.
